Search - tctmd.com

Displaying 361 - 380 of 498

Sort: Relevancy | Date

News Conference News TCT 2014

ABSORB II: Similar Clinical Outcomes, Less Angina with Bioresorbable Scaffold vs. EES

Yael L. Maxwell

September 14, 2014

News Conference News TCT 2014

ABSORB EXTEND: BVS Safe Out to 3 Years

September 14, 2014

News Conference News TCT 2014

ADAPT-DES: Stent Thrombosis Increased During First 30 Days After PCI in High-Risk Patients

September 13, 2014

News Daily News

PROTECT: Lower Stent Thrombosis Risk with Endeavor Emerges at 4 Years

L.A. McKeown

September 02, 2014

News Daily News

Outlook for Avoiding or Surviving Acute CVD, Stroke Much Improved Over Past Decade

September 02, 2014

News Conference News ESC 2014

FAMOUS-NSTEMI: FFR Guidance Reduces Revascularization in NSTEMI

Todd Neale

September 01, 2014

News Conference News ESC 2014

SOLID-TIMI 52: Darapladib Fails to Reduce Adverse Events After ACS

Yael L. Maxwell

August 31, 2014

News Daily News

Clinical Impact of DES Failure Depends on Timing

L.A. McKeown

August 07, 2014

News Industry News

Sanofi and Regeneron Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia

July 30, 2014

News Industry News

The Medicines Company Receives Market Authorization Renewal for Angiox® (Bivalirudin) from the European Medicines Agency and the European Commission

July 07, 2014

News Daily News

Study Highlights Disparity Between Pre-, Postmarket Study Outcomes for DES

Caitlin E. Cox

June 13, 2014

News Daily News

PROSPECT Substudy: Persistently High CRP Predicts Future MACE in ACS Patients After PCI

June 04, 2014

News Daily News

Nationwide Registry Shows Trends in DES Use Over a Decade

June 02, 2014

News Daily News

Nobori BES Equals Promus Element in Long Lesions

Jason Kahn

May 30, 2014

News Industry News

Data on Angiox (Bivalirudin Injection) in Heart Attack Patients Presented at EuroPCR and Published in European Heart Journal

May 22, 2014

News Industry News

Micell Technologies Announces Clinical Data from MiStent SES Studies Will Be Presented at EuroPCR 2014

May 15, 2014

News Daily News

Patients with Cardiac Arrest Fare Poorly After PCI

April 17, 2014

News Daily News

PLATO Analysis: No Sex-Based Difference in Ticagrelor’s Safety and Efficacy

April 16, 2014

News Daily News

Cardiac Rehab Reduces Late Lumen Loss, Improves Risk Profile in Patients with Long Lesions

April 14, 2014

News Daily News

Diabetes Drug Aleglitazar Fails to Reduce Ischemic Outcomes in Diabetics with Recent ACS

L.A. McKeown

April 11, 2014

Advertisement

ABSORB II: Similar Clinical Outcomes, Less Angina with Bioresorbable Scaffold vs. EES

ABSORB EXTEND: BVS Safe Out to 3 Years

ADAPT-DES: Stent Thrombosis Increased During First 30 Days After PCI in High-Risk Patients

PROTECT: Lower Stent Thrombosis Risk with Endeavor Emerges at 4 Years

Outlook for Avoiding or Surviving Acute CVD, Stroke Much Improved Over Past Decade

FAMOUS-NSTEMI: FFR Guidance Reduces Revascularization in NSTEMI

SOLID-TIMI 52: Darapladib Fails to Reduce Adverse Events After ACS

Clinical Impact of DES Failure Depends on Timing

Sanofi and Regeneron Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia

The Medicines Company Receives Market Authorization Renewal for Angiox® (Bivalirudin) from the European Medicines Agency and the European Commission

Study Highlights Disparity Between Pre-, Postmarket Study Outcomes for DES

PROSPECT Substudy: Persistently High CRP Predicts Future MACE in ACS Patients After PCI

Nationwide Registry Shows Trends in DES Use Over a Decade

Nobori BES Equals Promus Element in Long Lesions

Data on Angiox (Bivalirudin Injection) in Heart Attack Patients Presented at EuroPCR and Published in European Heart Journal

Micell Technologies Announces Clinical Data from MiStent SES Studies Will Be Presented at EuroPCR 2014

Patients with Cardiac Arrest Fare Poorly After PCI

PLATO Analysis: No Sex-Based Difference in Ticagrelor’s Safety and Efficacy

Cardiac Rehab Reduces Late Lumen Loss, Improves Risk Profile in Patients with Long Lesions

Diabetes Drug Aleglitazar Fails to Reduce Ischemic Outcomes in Diabetics with Recent ACS

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content